24649154
2013 Mar
The value of serum cholinesterase (ChE) level as a predictive marker in sorafenib therapy for advanced hepatocellular carcinoma (HCC) has not yet been investigated. The present retrospective study therefore analyzed the impact of the serum ChE level in 93 patients with advanced HCC treated with sorafenib. Patients were categorized into two groups: group A with pretreatment serum ChE â‰¥140 IU/l (n=46) and group B with pretreatment serum ChE
cholinesterase; hepatocellular carcinoma; liver dysfunction; prognostic factor; sorafenib.
